Patients Miss Timely Follow-up After Abnormal Chest CT

Article

Abnormal findings on lung cancer screening CT not always followed up in a timely manner.

Patients with abnormal results on chest CT screenings do not always receive timely follow-up, according to a study published in the Journal of the American College of Radiology.

Researchers from Harvard Medical School and Massachusetts General Hospital in Boston performed a study to determine the proportion of patients who received timely follow-up, defined as within 30 days of recommendation, after screening chest CTs detected an abnormality. Data from 376 patients were examined; 337 (90%) had abnormal chest CT findings and 184 (55%) had specific follow-up recommendations.

The results showed that only 102 of the 184 patients (55%) with recommendations received follow-up within 30 days. Patients who were most likely to be seen within the 30 days were those whose CTs were performed to evaluate pulmonary disease and those receiving care in community health centers. Twenty-seven patients were newly diagnosed with lung cancer; 18 (67%) had their first oncology visit within 30 days of diagnosis.

“Systems to support patients in obtaining recommended follow-up are needed to ensure that the benefits of lung cancer screening translate into usual clinical practice,” the authors wrote.

 

Recent Videos
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.